Year: 2013
Type: review
Abstract: Cardiovascular disease is the number one cause of mortality in the Western world.The heart responds to many cardiopathological conditions with hypertrophic growth by enlarging individual myocytes to augment cardiac pump function and decrease ventricular wall tension.Initially, such cardiac hypertrophic growth is often compensatory, but as time progresses these changes become maladaptive.Cardiac hypertrophy is the strongest predictor for the development of heart failure, arrhythmia, and sudden death.Here we discuss therapeutic avenues emerging from molecular and genetic studies of cardiovascular disease in animal models.The majority of these are based on intracellular signaling pathways considered central to pathologic cardiac remodeling and hypertrophy, which then leads to heart failure.We focus our discussion on selected therapeutic targets that have more recently emerged and have a tangible translational potential given the available pharmacologic agents that could be readily evaluated in human clinical trials.β-Adrenergic receptor signaling and associated kinases in cardiac hypertrophy and remodeling Inhibition of β-adrenergic receptor signaling is perhaps the most effective and frequently employed therapy in addressing negative Conflict of interest:The authors have declared that no conflict of interest exists.
DOI: 10.1172/jci62839
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2167407855